Core Viewpoint - The implementation of the new VAT law and its regulations starting January 1, 2026, will end the tax exemption previously enjoyed by profit-oriented medical beauty institutions in China, requiring them to pay VAT [3][4]. Group 1: Tax Policy Changes - The new VAT law explicitly excludes profit-oriented medical beauty institutions from the tax exemption that applies to medical services provided by qualified medical institutions [3][4]. - Prior to this change, many medical beauty institutions benefited from VAT exemptions due to their classification as medical service providers, which has now been clarified and restricted [4][5]. - The adjustment aims to eliminate the ambiguity surrounding the classification of medical beauty services and ensure that all similar services are subject to the same tax obligations [6][7]. Group 2: Industry Impact - The medical beauty industry in China has been rapidly growing, with market estimates exceeding 300 billion yuan, driven by increasing demand and a rising number of young consumers [5]. - The removal of the VAT exemption may lead to price increases in medical beauty services, although the extent of these increases will vary based on factors such as regional market conditions and individual business strategies [8][9]. - Experts suggest that while some lower-end services may see price hikes due to the new tax burden, high-end services may not be as affected due to their already high profit margins [9]. Group 3: Compliance and Business Model - The new tax regulations will require medical beauty institutions to establish a comprehensive input tax deduction system to mitigate their tax burden [9]. - The industry is expected to undergo a restructuring of its business models, particularly due to high marketing costs that are difficult to offset with VAT deductions [9].

医美价格受多重因素影响 随着增值税法及其实施条例在今年起实施，医美行业此前部分业务享受免税优惠将成为历史。 《中华人民共和国增值税法》和《中华人民共和国增值税法实施条例》自2026年1月1日起施行。其中， 增值税法在税收优惠一章中，明确了"医疗机构提供的医疗服务"免征增值税。增值税法实施条例将前 述"医疗机构"定义为"依据有关规定设立的具有医疗机构执业资格的机构，包括军队、武警部队各级各 类医疗机构，不包括营利性美容医疗机构。"。 第一财经记者从税务总局北京市税务局12366纳税缴费服务热线处了解到，今年之前增值税相关规定 中，并没有将营利性美容医疗机构排除在上述免税政策范围外。而从今年开始，只要是营利性美容医疗 机构，将不再享受上述免征增值税优惠政策。 上海国家会计学院副教授葛玉御告诉第一财经，在此前增值税制度下，国家对医疗机构提供的符合规定 的医疗服务给予免征增值税优惠政策，但并没有排除医美机构和医美服务。因此不少医美机构符合条件 医疗服务实际享受了免税优惠政策，而这在实务中存在争议。而今年起实施的增值税实施条例解决这一 争议，明确营利性医美机构不再享受上述免征增值税优惠政策，需要依法纳税。 所谓美容医疗 ...

证券日报网讯 1月5日，爱美客在互动平台回答投资者提问时表示，截至2025年12月31日，公司股东人 数为60075户。 （文章来源：证券日报） ...

Group 1 - The core viewpoint is that Huaxi Bio sees the South Korean market as a crucial area for international expansion, particularly in the rapidly growing medical aesthetics industry [2] - The China-Korea Business Forum highlighted discussions on manufacturing innovation, supply chain cooperation, and new consumer markets, with over 400 attendees from both countries [2] - Biomanufacturing is identified as a strategic high ground in the global technological revolution, with the "14th Five-Year Plan" emphasizing the need for forward-looking layouts in biomanufacturing and other future industries [2] Group 2 - Huaxi Bio, established in 2000 and listed on the STAR Market in 2019, specializes in the research and production of bioactive materials, holding a 44% share in the global hyaluronic acid raw material market and 70% in the domestic market [3] - The company entered the South Korean market in 2002 and has expanded into pharmaceuticals, medical aesthetics, cosmetics, and functional foods, with a new subsidiary established in Seoul in 2023 [3] - In the pharmaceutical sector, Huaxi Bio collaborates with top Korean companies in eye drops and joint injection products, while in medical aesthetics, its products cover over 90% of local production companies [3]

Core Viewpoint - Revance Therapeutics (01696) has announced that its injectable botulinum toxin type A (DaxibotulinumtoxinA-lanm, marketed as DAXXIFY in English) has passed quality standard inspections by the Chinese National Institute for Food and Drug Control, marking a significant step towards commercialization in China [1] Group 1: Product Development - DaxibotulinumtoxinA is designed for the temporary improvement of moderate to severe glabellar lines caused by the activity of the corrugator and/or procerus muscles in adults [1] - As of the announcement date, there are no other DaxibotulinumtoxinA products available for sale in China, indicating a first-mover advantage for the company [1] Group 2: Market Strategy - The successful inspection signifies that DaxibotulinumtoxinA meets the stringent quality, safety, and efficacy requirements set by Chinese regulatory authorities [1] - The company has secured its first commercial orders for DaxibotulinumtoxinA in the Chinese market, entering the commercialization phase [1] Group 3: Business Impact - The company views DaxibotulinumtoxinA as a strategic cornerstone for its injectable filler business, enhancing product diversity and providing consumers with more quality options [1] - DaxibotulinumtoxinA is expected to serve as a second growth engine, contributing to sustained consumable revenue and reinforcing the company's leading position in the global beauty and health industry [1]

Core Viewpoint - Furuya Medical Technology (01696.HK) has announced that its reauthorized injectable botulinum toxin type A (DaxibotulinumtoxinA-lanm, trademarked as 达希斐® in China and DAXXIFY® in English) has passed quality standard inspections by the China National Institute for Food and Drug Control, marking a significant step towards commercialization in China [1] Group 1 - The product is intended for the temporary improvement of moderate to severe glabellar lines caused by the activity of the corrugator and/or procerus muscles in adults [1] - As of the announcement date, there are no other DaxibotulinumtoxinA products available for sale in China, indicating a first-mover advantage for the company [1] - The successful inspection signifies that DaxibotulinumtoxinA has met the stringent quality, safety, and efficacy requirements set by Chinese regulatory authorities [1] Group 2 - The company has secured its first commercial orders for DaxibotulinumtoxinA in the Chinese market, officially entering the commercialization phase [1] - DaxibotulinumtoxinA is viewed as a strategic cornerstone for the company's injectable filler business, enhancing product diversity and providing more quality options for consumers [1] - The product is expected to serve as a second growth engine, contributing to sustained consumable revenue and reinforcing the company's leading position in the global beauty and health industry [1]

Group 1 - CITIC Securities maintains a "Buy" rating for Huahong Semiconductor (01347.HK) with a target price of HKD 100, highlighting its leading position in specialty process wafer foundry and strong growth potential from capacity expansion and acquisitions [1] - CITIC Securities also maintains a "Buy" rating for SiHuan Pharmaceutical (00460.HK) with a target price of HKD 1.6, noting rapid growth in its medical aesthetic products and strong sales performance of new regenerative products [1] - GF Securities maintains a "Buy" rating for Yum China (09987.HK) with a target price of HKD 453.62, citing improved same-store sales and growth driven by new product iterations and marketing strategies [1] Group 2 - GF Securities initiates coverage on Laoputang Gold (06181.HK) with a "Buy" rating and a target price of HKD 775.64, emphasizing its leading position in handcrafted gold jewelry and strong growth potential from store expansion [2] - GF Securities initiates coverage on Yue Yuen Industrial (00551.HK) with a "Buy" rating and a target price of HKD 19.99, highlighting its status as the largest athletic shoe manufacturer and expected performance recovery [3] Group 3 - Cinda International maintains a "Buy" rating for Hesai Technology (02525.HK), noting its leadership in the global LiDAR market and significant growth in production and market share [4] - Zhongtai Securities initiates coverage on China Resources Land (01109.HK) with an "Accumulate" rating, reporting strong revenue and profit growth along with a healthy financial structure [5] Group 4 - First Shanghai initiates coverage on Jaxin International Resources (03858.HK) with a "Buy" rating and a target price of HKD 82.4, highlighting its world-class tungsten resources and strong profit growth potential [6] - Kaiyuan Securities initiates coverage on Beautiful Pastoral Medical Health (02373.HK) with a "Buy" rating, emphasizing its differentiated business model and effective customer acquisition strategies [7] Group 5 - CICC maintains an "Outperform" rating for Standard Chartered Group (02888.HK), noting better-than-expected Q2 2025 performance driven by significant growth in non-interest income [8]

21世纪经济报道记者李域 2025年落下帷幕，公募基金成绩单出炉，主动权益基金交出了亮眼的业绩答卷。 翻开融通产业趋势的季报，超额收益来源清晰可见，AI、新消费与创新药。李进将其归结为一种"时代感"的投资。 "巨大的投资收益往往来源于需求大幅扩张、产业规模快速增长的领域。"李进表示，他的日常工作聚焦于追踪社会变迁与产业演进，着力寻找 存在阶段性市场效率缺失、需求尚未得到充分满足的行业。因此，他对成长性行业抱有更高关注度，对这些方向投入更多研究精力，并保持持 续紧密的跟踪。 李进于2023年3月开始担任基金经理，当时就将投资组合全面聚焦于人工智能方向。彼时，市场对该趋势仍存疑虑，但李进判断人工智能代表 一次重大的技术进步，其影响可能超越互联网。其核心依据源于ChatGPT所展现出的用户增长态势——用户量从零到一亿仅用时一个月，如此 高速的扩张历程前所未有。 在形成初步判断后，他开展了产业链验证。自2023年初起，通过调研，观察到光模块等环节出现"每周爆单"的现象，进一步印证了人工智能产 业的真实景气度，从而确立了该方向的配置决策。 2023年年中，他关注到家庭成员开始使用含有胶原蛋白成分的化妆品，由此切入对该细 ...

Summary of High-End Consumer Market Recovery Industry Overview - The high-end consumer market has shown signs of recovery from the second half of 2025, particularly in the luxury goods, mid-to-high-end beauty products, and high-end real estate sectors in the Asia-Pacific region [3][4][5]. Key Insights and Arguments - **Market Recovery Indicators**: - Hainan's duty-free sales turned positive for the first time in 18 months starting September 2025, with strong performance during the New Year period [3]. - The gambling industry experienced double-digit year-on-year growth in October 2025 [3]. - High-end real estate retail sales saw double-digit growth during the National Day holiday [4]. - **Support from High-Net-Worth Individuals**: - High-net-worth individuals contributed nearly 50% to the luxury goods market, with their spending patterns shifting towards gold and away from real estate [4][6]. - This demographic's marginal propensity to consume is stronger than that of the middle class, providing sustained momentum for high-end consumption [6]. - **Shift in Consumption Structure**: - The high-end consumption structure is transitioning from traditional goods to experiential services, with a notable increase in demand for pure experiential services post-pandemic [4][7]. - Domestic brands, particularly in jewelry and cosmetics, are increasingly entering the high-end market, with Gen Z consumers showing greater acceptance of local high-end brands [4][7]. - **Gold Jewelry Market Growth**: - The gold jewelry segment is expected to grow significantly, with the ancient gold craftsmanship gaining popularity due to its modern aesthetic appeal [8][10]. - The ancient gold market is projected to grow at over 20% annually over the next 3-5 years, driven by increased consumer awareness and acceptance [11]. Additional Important Insights - **Emerging Brands**: - Key players in the high-end ancient gold market include brands like Laopu, Junpei, Linchao, and Baolan, each with unique design philosophies and market strategies [12]. - Laopu aims to become a world-class gold brand, expanding its presence in premium shopping areas and planning international market entry [12][14]. - **Cosmetics Industry Trends**: - The cosmetics sector is experiencing a clear trend towards premiumization, with domestic brands like Maogeping performing well [16][20]. - New sales channels, particularly Douyin, are providing growth opportunities for emerging brands, although traditional platforms like Taobao are regaining prominence [18]. - **Medical Aesthetics Sector**: - The medical aesthetics industry is expected to recover, benefiting from new material approvals and the rising share of non-surgical procedures [19]. - **Investment Recommendations**: - Water Sheep Co. and Maogeping are highlighted as key investment targets, with expectations of significant revenue growth driven by brand expansion and acquisitions [20][21]. Market Outlook - The high-end consumer market is projected to achieve revenues of approximately 45 to 50 billion yuan in 2025, with a potential growth of 30% to 40% in 2026 [15].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2]. Core Insights - The cosmetics and medical beauty sector outperformed the market, with the Shenwan Beauty Care Index rising by 0.2% from December 26 to December 31, 2025, while the Shenwan Cosmetics Index increased by 1.0% [4][5]. - Lin Qingxuan successfully completed its IPO on December 30, 2025, attracting significant investor attention. The company, founded in 2003, reported a revenue growth from 690 million yuan in 2022 to 1.21 billion yuan in 2024, with a compound annual growth rate (CAGR) of 32.7% [4][10]. - Upward confidence in the company is reflected in the share buyback by senior management at Shangmei Co., with a total of 835,900 shares purchased in December 2025, amounting to approximately 66.32 million HKD [4][10]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector showed strong performance, with the Shenwan Beauty Care Index increasing by 0.2% during the specified period, outperforming the market [4][5]. - The top-performing stocks included Yanjiang Co. (+14.3%), Shuiyang Co. (+9.5%), and Qingsong Co. (+7.0%), while Shangmei Co. saw a decline of 18.6% [6]. Key Company Updates - Lin Qingxuan's IPO on the Hong Kong Stock Exchange was a significant event, marking it as a leading high-end domestic skincare brand. The company has a strong market presence with a focus on camellia oil-based products [4][10]. - Shangmei Co. demonstrated management confidence through share buybacks, indicating a positive outlook for future growth [4][10]. E-commerce and AI Integration - The report highlights the robust foundation of the e-commerce agency business, particularly for companies like Yiwan Yichuang, which is leveraging AI to enhance operational efficiency and performance [11][12]. - The e-commerce agency sector is experiencing a resurgence, driven by increased demand for brand representation on platforms like Alibaba [12][13]. Market Data - The retail sales of cosmetics in China for the first eleven months of 2025 reached 428.5 billion yuan, reflecting a year-on-year growth of 4.8% [16]. - The report indicates that the market for PDRN components is expected to reach 285 million USD globally by 2029, with China projected to capture 34% of this market [21]. Competitive Landscape - The domestic skincare market is becoming increasingly competitive, with local brands gaining market share against international competitors. The report notes that local brands now occupy five of the top ten positions in market share [24]. - The report anticipates that the trend of domestic brands gaining market share will continue, particularly in the context of rising consumer preference for local products [24].